Protalix Biotherapeutics Announced A Collaboration With Secarna Pharmaceuticals For The Discovery Of Novel Antisense Oligonucleotide Therapies Against Multiple Targets For Rare Renal Indications, Deal Terms Were Not Disclosed
Benzinga Newsdesk 10 months ago
BiotechNewsHealth CareContractsGeneral
Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indicationsProtalix is granted an
- Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications
- Protalix is granted an exclusive option to license any active compounds derived from the research for potential clinical development and commercialization